29-NOV-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

91% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1564 918 59% 1006 -557 985 -579
ERLYTX 76 85 112% 93 17 96 20
GI 479 179 37% 196 -282 194 -285
GU 450 410 91% 449 0 443 -7
GYN 57 0 0% 0 -57 0 -57
LEUK 150 126 84% 138 -11 138 -12
LUNG 524 148 28% 162 -361 225 -299
LYMPH 172 368 214% 403 231 394 222
MELAN 55 275 500% 301 246 299 244
MMYEL 147 135 92% 147 0 171 24
MULT 0 17   18 18 17 17
OTHER 0 35   38 38 40 40
PREV 0 2   2 2 3 3
SXQOL 0 2   2 2 2 2
Total 3674 2700   2955 -714 3007 -667

29-NOV-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

91% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 1   1 1 1 1
BREAST 43 0 0% 0 -43 0 -43
CCD 0 102   111 111 119 119
ERLYTX 0 10   10 10 10 10
GU 0 0   0 0 0 0
LEUK 69 616 893% 675 606 672 603
LUNG 43 284 660% 311 268 292 249
LYMPH 53 1 2% 1 -51 1 -52
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 32   35 35 34 34
PEOLC 0 114   124 124 117 117
PREV 0 180   197 197 226 226
SURV 0 17   18 18 18 18
SXQOL 888 510 57% 559 -328 587 -301
Total 1188 1867   2042 856 2077 889

29-NOV-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

91% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 3   3 3 3 3
BREAST 1607 918 57% 1006 -600 985 -622
CCD 0 102   111 111 119 119
ERLYTX 76 95 125% 104 28 106 30
GI 479 179 37% 196 -282 194 -285
GU 450 410 91% 449 0 443 -7
GYN 57 0 0% 0 -57 0 -57
LEUK 219 742 339% 813 594 810 591
LUNG 567 432 76% 473 -93 517 -50
LYMPH 225 369 164% 404 179 395 170
MELAN 55 275 500% 301 246 299 244
MMYEL 239 135 56% 147 -91 171 -68
MULT 0 17   18 18 17 17
OTHER 0 67   73 73 74 74
PEOLC 0 114   124 124 117 117
PREV 0 182   199 199 229 229
SURV 0 17   18 18 18 18
SXQOL 888 512 58% 561 -326 589 -299
Total 4862 4569   5000 144 5086 224

29-NOV-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

91% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1018 569 56% 623 -394 606 -412
ERLYTX 76 46 61% 50 -25 53 -23
GI 421 130 31% 142 -278 143 -278
GU 375 344 92% 377 2 372 -3
GYN 57 0 0% 0 -57 0 -57
LEUK 122 76 62% 83 -38 85 -37
LUNG 441 96 22% 105 -335 143 -298
LYMPH 129 234 181% 256 127 249 120
MELAN 55 173 315% 189 134 190 135
MMYEL 85 87 102% 95 10 109 24
MULT 0 7   7 7 7 7
OTHER 0 35   38 38 40 40
PREV 0 2   2 2 3 3
SXQOL 0 2   2 2 2 2
Total 2779 1801   1969 -805 2002 -777

29-NOV-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

91% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 1   1 1 1 1
BREAST 16 0 0% 0 -16 0 -16
CCD 0 91   99 99 105 105
ERLYTX 0 10   10 10 10 10
GU 0 0   0 0 0 0
LEUK 69 278 403% 304 235 312 243
LUNG 30 174 580% 190 160 179 149
LYMPH 53 1 2% 1 -51 1 -52
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 32   35 35 34 34
PEOLC 0 79   86 86 82 82
PREV 0 180   197 197 226 226
SURV 0 17   18 18 18 18
SXQOL 750 340 45% 372 -377 393 -357
Total 1010 1203   1313 305 1361 351

29-NOV-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

91% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 3   3 3 3 3
BREAST 1034 569 55% 623 -410 606 -428
CCD 0 91   99 99 105 105
ERLYTX 76 56 74% 61 -14 63 -13
GI 421 130 31% 142 -278 143 -278
GU 375 344 92% 377 2 372 -3
GYN 57 0 0% 0 -57 0 -57
LEUK 191 354 185% 388 197 397 206
LUNG 471 270 57% 295 -175 322 -149
LYMPH 182 235 129% 257 75 250 68
MELAN 55 173 315% 189 134 190 135
MMYEL 177 87 49% 95 -81 109 -68
MULT 0 7   7 7 7 7
OTHER 0 67   73 73 74 74
PEOLC 0 79   86 86 82 82
PREV 0 182   199 199 229 229
SURV 0 17   18 18 18 18
SXQOL 750 342 46% 374 -375 395 -355
Total 3789 3006   3286 -497 3365 -424

29-NOV-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

91% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 65 912 1403% 999 934 978 913
CCD 0 102   111 111 119 119
ERLYTX 0 2   2 2 2 2
GI 81 68 84% 74 -6 74 -7
GU 215 269 125% 294 79 290 75
LEUK 0 40   43 43 45 45
LUNG 53 72 136% 78 25 75 22
LYMPH 7 75 1071% 82 75 80 73
MELAN 0 0   0 0 0 0
MMYEL 0 125   137 137 158 158
OTHER 0 31   33 33 33 33
PEOLC 0 114   124 124 117 117
PREV 0 182   199 199 200 200
SURV 0 17   18 18 18 18
SXQOL 880 512 58% 561 -318 589 -291
Total 1301 2521   2755 1456 2778 1477

29-NOV-2025 6:11

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm. Phase Study Stat
Center		 Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure
    A032102 ALLIANCE     2      
    NRG-HN014 NRG     1      
BREAST II NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   7     Dec-2022 Temp Close
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1     May-2022 Temp Close
  III A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib ALLIANCE 06JAN2021:00:00:00   55   0.0  
    A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab ALLIANCE 03MAY2023:00:00:00   45   3.7  
    A012301 Breast, Early Stg, Tamoxifen ALLIANCE 05FEB2025:00:00:00   44   6.8  
    MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG 30MAY2018:00:00:00   63   1.7  
    NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG 07JUN2021:00:00:00   30   1.3  
    NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG 31AUG2023:00:00:00   28   2.3  
    S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva SWOG 30OCT2023:00:00:00 24 277 960 17.2 Feb-2029
    S2212 Breast, TNBC, Neoadj Chemo + Pembro SWOG 21JUL2023:00:00:00 28 1024 2400 62.7 Aug-2027
CCD III S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 88 436 498 5.3 Oct-2026
    S2417CD Colrec Surv, Follow-up w/ CTAC site SWOG 04AUG2025:00:00:00 3 11 654 2.9 > 15 Yrs
  OTHER A231602C Blood Cancer, Assess Financial Difficulty ALLIANCE 15MAR2019:00:00:00   4     Feb-2021 Temp Close
    ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   54     Aug-2022 Temp Close
    EAQ221CD Breast, Metastatic, Imp. Adherence ECOG-ACRIN 31OCT2023:00:00:00   4   0.3  
    EAQ222CD CostCOM, Cancer Patients, OOP Cost Com ECOG-ACRIN 29FEB2024:00:00:00   31   2.3  
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 28AUG2015:00:00:00   9   0.2  
    EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib SWOG 06MAR2023:00:00:00 32 32 33 1.7 Nov-2025
  II-III S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo SWOG 02DEC2021:00:00:00 47 131 189 5.3 Sep-2026
  III AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult COG 08MAY2017:00:00:00   4   0.2  
  OTHER EAY191 ComboMATCH ECOG-ACRIN 06MAR2023:00:00:00   21   0.8  
GI II CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG 05JUN2023:00:00:00   5   0.2  
    EA2192 Panc, APOLLO ECOG-ACRIN 29APR2021:00:00:00   6   0.2  
    S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect SWOG 16DEC2019:00:00:00 71 45 54 0.5 Apr-2027
    S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs SWOG 14OCT2021:11:13:50 49 83 154 2.3 May-2028
  II-III EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab ECOG-ACRIN 17JAN2019:00:00:00   6   0.0  
    NRGGI008 Colon, Stg III, Adj Chemo NRG 10MAR2022:00:00:00   47   2.3  
    S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo SWOG 06MAY2024:00:00:00 18 69 224 6.2 Dec-2027
  III A021806 Pancreas, Perioperative vs Adjuvant Chemo ALLIANCE 01JUL2020:00:00:00   37   0.7  
    A022101 Colorectal, Metastatic, Ablative Tx ALLIANCE 10JAN2023:00:00:00   1   0.0  
    A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo ALLIANCE 11JAN2023:00:00:00   36   1.2  
    CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG 29FEB2024:00:00:00   8   0.5  
    EA2222 Colorectal, Stg II-III, Hep Art Infusion ECOG-ACRIN 19OCT2023:00:00:00   6   0.5  
    NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT NRG 06MAR2019:00:00:00   1   0.0  
GU II A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   28   0.8  
    A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   28   0.2  
    A031801 GU, mRCC, Cabozantinib ± Radium-223 ALLIANCE 13DEC2019:00:00:00   15   0.0  
    NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx NRG 08DEC2021:00:00:00   23   1.0  
    NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG 30JUN2022:00:00:00   10   0.5  
    S2200 pRCC, Adv, Cabo ± Atezo SWOG 19SEP2022:00:00:00 38 35 200 0.5 > 15 Yrs
    S2210 Pros, High Risk, BRCA, Neoadj Carbo SWOG 14AUG2023:00:00:00 27 6 44 0.3 Apr-2035
    S2427 Blad, MIBC, RT + Pembrolizumab SWOG 04SEP2025:00:00:00 2 1 111    
  II-III A032103 Urothelial, All Stg, MRD-Based Adj Tx ALLIANCE 09JAN2024:00:00:00   32   2.2  
    EA8192 Blad, High Grade UTUC, Durv + Chemo ECOG-ACRIN 06MAY2021:00:00:00   6   0.3  
  III A032201 Renal Cell, High-Risk, Pembro+Tiv ALLIANCE 05FEB2025:00:00:00   4   0.7  
    CCTG-PR26 Prostate, Cast Sensitive, Docetax CCTG 30JAN2025:00:00:00   1   0.2  
    EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT ECOG-ACRIN 08SEP2017:00:00:00   24   1.3  
    EA8191 Pros, Local vs Systemic Thrpy ECOG-ACRIN 08OCT2020:00:00:00   66   0.2  
    NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG 05MAR2020:00:00:00   16   0.3  
    NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG 03NOV2021:00:00:00   66   0.7  
    NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG 13NOV2023:00:00:00   13   0.8  
    S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 86 976 1273 10.0 Apr-2028
    S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only SWOG 16NOV2020:00:00:00 60 140 336 2.0 Dec-2033
    S1937 Blad, Mets, Eribulin + Gem vs SOC SWOG 16FEB2021:00:00:00 57 120 184 5.3 Oct-2026
    S2312 Pros, MCRPC, Cab +/- Carb SWOG 03SEP2024:00:00:00 14 36 500 2.7 Apr-2040
LEUK I-II S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 SWOG 17AUG2020:00:00:00   24 67   Oct-2025 Temp Close
  II 21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone SWOG 15MAY2025:00:00:00 6 0 55 0.0 > 15 Yrs
    A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat ALLIANCE 16NOV2018:00:00:00   5   0.0  
    EA9213 T-ALL, dara-hyal for chemo refractory MRD ECOG-ACRIN 16JUN2022:00:00:00   3   0.0  
    MM1OA-EA02 MyeloMATCH: AML, New Dx, Ven+HMA ECOG-ACRIN 06JUN2024:00:00:00   9   0.8  
    MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena SWOG 01APR2025:00:00:00   8 102   Oct-2025 Temp Close
    MM1YA-CTG01 MyeloMATCH: AML, New/Young/Int, Ven+Chemo CCTG 18JUL2024:00:00:00   6   0.7  
    MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental SWOG 16MAY2024:00:00:00 18 52 335 5.8 Nov-2029
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   44   0.0  
    EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab ECOG-ACRIN 14OCT2020:00:00:00   51   1.2  
    S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O SWOG 14DEC2020:00:00:00 59 166 247 3.0 Jan-2028
  OTHER MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials SWOG 16MAY2024:00:00:00 18 813   54.0  
LUNG II EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 ECOG-ACRIN 05APR2018:00:00:00   4   0.0  
    S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu SWOG 03APR2023:00:00:00 31 23 66 0.5 Dec-2032
    S1900J MET Amplification: Amivantamab Hyaluronidase SWOG 27SEP2024:10:59:58 14 3 88 0.2 > 15 Yrs
    S1900K MET Exon 14: Tepotinib +/- Ramucirumab SWOG 18DEC2023:00:00:00 23 16 56 1.3 Apr-2028
    S1933 NSCLC, Stg II-III, RT + Atezo SWOG 15JUN2020:10:15:53 65 47 47 0.5 Nov-2025
    S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx SWOG 08SEP2025:00:00:00 2 0 900    
  II-III A082002 Lung, Adv, Systemic Tx +/- SBRT ALLIANCE 21DEC2021:00:00:00   4   0.0  
    S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab SWOG 28APR2025:10:50:48 7 38 378 6.0 Jul-2030
  III A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO ALLIANCE 03JUN2020:00:00:00   100   1.3  
    EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 ECOG-ACRIN 22OCT2020:00:00:00   25   0.3  
    EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno ECOG-ACRIN 15FEB2024:00:00:00   4   0.3  
    NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG 10MAY2023:00:00:00   5   0.3  
    S1827 SCLC, MRI Surveillance +/- PCI SWOG 10JAN2020:00:00:00 70 299 668 3.0 Jan-2036
    S2402 NSCLC, All Stg, Periop Vs Adj Tx ALLIANCE 11DEC2024:00:00:00   4   0.2  
    S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance SWOG 14MAR2025:00:00:00 8 5 306 0.7 > 15 Yrs
  OTHER LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 82 3825   30.2  
LYMPH II A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P ALLIANCE 30JUL2021:00:00:00   19   0.3  
    S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation SWOG 23FEB2023:11:55:36 33 175 396 6.2 Oct-2028
    S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa SWOG 30JUN2023:11:49:39   34 241   Oct-2025 Temp Close
  II-III S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP SWOG 19MAR2021:00:00:00   136 422   Apr-2025 Temp Close
  III A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub ALLIANCE 08SEP2023:00:00:00   25   1.2  
    AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy COG 28APR2023:00:00:00   77   3.8  
    EA4232 Lymph, Peri T Cell, Auto Stem ECOG-ACRIN 30JAN2025:00:00:00   1   0.2  
    S2308 FL, LTB, Mosunetuzumab vs Rituximab SWOG 01AUG2024:00:00:00 15 220 600 20.3 May-2027
MELAN II A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo ALLIANCE 01JUN2022:00:00:00   1   0.0  
  II-III EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 10SEP2015:00:00:00   77   1.0  
MMYEL II EAA173 MYEL, SMM, Rd +/- Daratumumab ECOG-ACRIN 30APR2019:00:00:00   39   0.3  
    S2005 WM, Prev. Untreated, I/R +/- Venetoclax SWOG 24JUN2021:00:00:00   22 92   Nov-2025 Temp Close
  III EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) ECOG-ACRIN 27OCT2020:00:00:00   46   1.0  
    S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 77 1338 1100 0.3 Jun-1966
    S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D SWOG 30MAY2023:00:00:00 29 105 510 4.3 Aug-2033
    S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT SWOG 01DEC2023:00:00:00 23 29 338 2.7 Jun-2035
MMYL II A062102 MMYL, All Stg, Iberdomide Tx ALLIANCE 04APR2024:00:00:00   0   0.0  
MULT II S2101 Melan or HNSCC, Adv, Cabo + Nivo SWOG 14OCT2022:10:48:23 37 71 220 2.8 Mar-2030
OTHER I NRGGY022 Mult Site/Stg, Carboplat Clearance Predict NRG 18NOV2019:00:00:00   3   0.0  
  II 21CTP.HN01 HN, Recur/Met, Amivantamab + Chemo SWOG 15SEP2025:00:00:00 2 0 50    
    A071701 BRAIN, Met, Geno-guided trial ALLIANCE 15AUG2019:00:00:00   2   0.0  
    A092105 Nasopharyngeal, Adv, Niv/Ip +- Cab ALLIANCE 18SEP2023:00:00:00   1   0.2  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   22   0.0  
    EA3191 HN, High Risk HNSCC, Adj +/- Pembro ECOG-ACRIN 08JAN2021:00:00:00   13   0.0  
    NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx NRG 16APR2024:00:00:00   1   0.2  
    NRGHN010 HER2+ SGC, T-DM1 vs TH NRG 30SEP2022:00:00:00   4   0.0  
  II-III A072201 Glioblastoma, Recurrent, Block vs SOC ALLIANCE 03SEP2024:00:00:00   2   0.3  
    NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG 12AUG2022:00:00:00   3   0.3  
    NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG 08JUL2020:00:00:00   4   0.2  
    NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG 27OCT2021:00:00:00   19   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   8   0.2  
  III A092205 HN Squamous, Rec/Metas, Pem vs Pem+Cet ALLIANCE 21NOV2024:00:00:00   1   0.2  
    AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo COG 30JUL2018:00:00:00   5     Temp Close
    CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG 29SEP2022:00:00:00   1   0.0  
    CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy CCTG 25MAY2018:00:00:00   1   0.0  
    EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox ECOG-ACRIN 13JUN2024:00:00:00   10   1.3  
    NRGBN003 Mening, Grd II, Observation vs Irradiation NRG 14JUN2017:00:00:00   3   0.0  
    NRGBN011 Brain, Lomustine + Temo vs Temo NRG 29NOV2021:00:00:00   15   0.7  
    NRGBN013 Brain, Intact Metas, SRS vs FSRS NRG 28AUG2024:00:00:00   5   0.3  
    NRGCC014 High Risk, Bone Meta, Radiation Tx NRG 14APR2025:00:00:00   18   3.0  
    NRGGY036 Ovary, All Stg, Olaparib +/- Bevac NRG 16JAN2025:00:00:00   3   0.3  
  OTHER A151804 irAEs, National Biorepository to Adv Studies ALLIANCE 31JAN2020:00:00:00   48   0.7  
PEOLC III S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 98 380 491 6.3 Apr-2027
    S2408 Panc Fistula Prevention, Lanreotide SWOG 14FEB2025:00:00:00 9 47 274 7.5 May-2028
PREV II EA2185 Panc, Impact of Panc Cyst Surveillance ECOG-ACRIN 16JAN2020:00:00:00   20   0.2  
  III NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG 06OCT2021:00:00:00   122   8.7  
  OTHER A212102 Blind Ref Set for Multicancer Early Detection ALLIANCE 01AUG2022:00:00:00   265   8.7  
    NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG 23JUN2020:00:00:00   13   0.2  
SURV OTHER EAQ211 Lymph, Survivors, Health Disp. AYA ECOG-ACRIN 30AUG2023:00:00:00   18   2.5  
SXQOL III A211901 Cancer survivors who smoke, txt cessation ALLIANCE 01DEC2021:00:00:00   15   0.2  
    A222004 Mult, Olanza vs Megestrol for Anorexia ALLIANCE 15OCT2021:00:00:00   7   0.0  
    ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis COG 14AUG2023:00:00:00   7   0.3  
    NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG 19SEP2022:00:00:00   15   0.2  
    NRGCC011 Breast, Survivors, Cog Training NRG 02FEB2024:00:00:00   38   0.5  
    NRGCC015 E-Mindfulness After Breast Cancer NRG 12JUN2025:00:00:00   0   0.0  
    S2205 ICE COMPRESS: Reduction of CIPN from Taxanes SWOG 16MAR2023:00:00:00 32 502 777 23.7 Oct-2026
  OTHER S2013 I-CHECKIT: ICI toxicity risk prediction study SWOG 16AUG2021:00:00:00 51 2342 3609 21.8 Sep-2030
  PILOT EAQ202 Improving AYA PROs in EA Trials ECOG-ACRIN 28OCT2021:00:00:00   44   0.2  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

29-NOV-2025 6:11

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase Comm. Int
grp		 Stat
Center		 Study NCIPROTO CA
Cntrl
Study		 Temp
Close
OTHER CCD     EAQ221CD Breast, Metastatic, Imp. Adherence   Y  
        EAQ222CD CostCOM, Cancer Patients, OOP Cost Com   Y  
    Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y Y
    Y ALLIANCE A231602C Blood Cancer, Assess Financial Difficulty A231602CD Y Y
  ERLYTX Y ECOG-ACRIN EAY191 ComboMATCH EAY191 N  
  LEUK Y SWOG MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials MYELOMATCH N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
  OTHER Y ALLIANCE A151804 irAEs, National Biorepository to Adv Studies A151804 N  
  PREV Y ALLIANCE A212102 Blind Ref Set for Multicancer Early Detection A212102 Y  
    Y NRG NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG-CC008 Y  
  SURV Y ECOG-ACRIN EAQ211 Lymph, Survivors, Health Disp. AYA EAQ211 Y  
  SXQOL Y SWOG S2013 I-CHECKIT: ICI toxicity risk prediction study S2013 Y  
I OTHER Y NRG NRGGY022 Mult Site/Stg, Carboplat Clearance Predict NRG-GY022 N  
I-II LEUK Y SWOG S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 S1905 N Y
II BREAST Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N Y
  ERLYTX Y SWOG EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib EAY191-S3 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI     EA2192 Panc, APOLLO   N  
    Y SWOG S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect S1922 N  
    Y SWOG S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs S2104 N  
    Y CCTG CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG-NE1 Y  
  GU Y SWOG S2200 pRCC, Adv, Cabo ± Atezo S2200 N  
    Y SWOG S2427 Blad, MIBC, RT + Pembrolizumab S2427 N  
    Y SWOG S2210 Pros, High Risk, BRCA, Neoadj Carbo S2210 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
    Y NRG NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx NRG-GU011 Y  
    Y NRG NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG-GU012 N  
    Y ALLIANCE A031801 GU, mRCC, Cabozantinib ± Radium-223 A031801 Y  
  LEUK N   21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone   N  
        EA9213 T-ALL, dara-hyal for chemo refractory MRD   N  
    Y SWOG MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena MM1OA-S03 N Y
    Y SWOG MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental MM1YA-S01 N  
    Y ECOG-ACRIN MM1OA-EA02 MyeloMATCH: AML, New Dx, Ven+HMA MM1OA-EA02 N  
    Y ALLIANCE A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat A041703 N  
    Y CCTG MM1YA-CTG01 MyeloMATCH: AML, New/Young/Int, Ven+Chemo MM1YA-CTG01 N  
  LUNG Y SWOG S1933 NSCLC, Stg II-III, RT + Atezo S1933 N  
    Y SWOG S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu S1900G N  
    Y SWOG S1900K MET Exon 14: Tepotinib +/- Ramucirumab S1900K N  
    Y SWOG S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx S2409 N  
    Y SWOG S1900J MET Amplification: Amivantamab Hyaluronidase S1900J N  
    Y ECOG-ACRIN EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 EA5162 N  
  LYMPH Y SWOG S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa S2207 Y Y
    Y SWOG S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation S2114 N  
    Y ALLIANCE A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P A051902 N  
  MELAN     A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo   N  
  MMYEL Y SWOG S2005 WM, Prev. Untreated, I/R +/- Venetoclax S2005 N Y
    Y ECOG-ACRIN EAA173 MYEL, SMM, Rd +/- Daratumumab EAA173 Y  
  MMYL     A062102 MMYL, All Stg, Iberdomide Tx   N  
  MULT Y SWOG S2101 Melan or HNSCC, Adv, Cabo + Nivo S2101 N  
  OTHER N   21CTP.HN01 HN, Recur/Met, Amivantamab + Chemo   N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y NRG NRGHN010 HER2+ SGC, T-DM1 vs TH NRG-HN010 N  
    Y ALLIANCE A071701 BRAIN, Met, Geno-guided trial A071701 N  
    Y NRG NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx NRG-GY032 N  
    Y ECOG-ACRIN EA3191 HN, High Risk HNSCC, Adj +/- Pembro EA3191 N  
    Y ALLIANCE A092105 Nasopharyngeal, Adv, Niv/Ip +- Cab A092105 N  
  PREV Y ECOG-ACRIN EA2185 Panc, Impact of Panc Cyst Surveillance EA2185 Y  
PILOT SXQOL Y ECOG-ACRIN EAQ202 Improving AYA PROs in EA Trials EAQ202 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N Y
  ERLYTX Y SWOG S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo S2012 N  
  GI Y SWOG S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo S2303 Y  
    Y ECOG-ACRIN EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab EA2174 N  
    Y NRG NRGGI008 Colon, Stg III, Adj Chemo NRG-GI008 N  
  GU     A032103 Urothelial, All Stg, MRD-Based Adj Tx   Y  
    Y ECOG-ACRIN EA8192 Blad, High Grade UTUC, Durv + Chemo EA8192 N  
  LUNG Y SWOG S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab S1800E N  
    Y ALLIANCE A082002 Lung, Adv, Systemic Tx +/- SBRT A082002 Y  
  LYMPH Y SWOG S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP S1918 Y Y
  MELAN Y ECOG-ACRIN EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y ALLIANCE A072201 Glioblastoma, Recurrent, Block vs SOC A072201 N  
    Y NRG NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG-HN006 Y  
    Y NRG NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG-HN009 Y  
    Y NRG NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG-GY026 Y  
III BREAST Y SWOG S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva S2206 Y  
    Y SWOG S2212 Breast, TNBC, Neoadj Chemo + Pembro S2212 Y  
    Y CCTG MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG MA.39 Y  
    Y ALLIANCE A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib A011801 Y  
    Y ALLIANCE A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab A012103 Y  
    Y NRG NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG-BR009 Y  
    Y ALLIANCE A012301 Breast, Early Stg, Tamoxifen A012301 Y  
    Y NRG NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG-BR007 Y  
  CCD Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y SWOG S2417CD Colrec Surv, Follow-up w/ CTAC site S2417CD Y  
  ERLYTX Y COG AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult AGCT1531 Y  
  GI     A022101 Colorectal, Metastatic, Ablative Tx   N  
    Y NRG NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT NRG-GI006 Y  
    Y CCTG CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG-CO32 Y  
    Y ECOG-ACRIN EA2222 Colorectal, Stg II-III, Hep Art Infusion EA2222 N  
    Y ALLIANCE A021806 Pancreas, Perioperative vs Adjuvant Chemo A021806 Y  
    Y ALLIANCE A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo A022102 N  
  GU N   S2312 Pros, MCRPC, Cab +/- Carb   N  
    Y SWOG S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1937 Blad, Mets, Eribulin + Gem vs SOC S1937 N  
    Y SWOG S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only S1931 N  
    Y ALLIANCE A032201 Renal Cell, High-Risk, Pembro+Tiv A032201 Y  
    Y ECOG-ACRIN EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT EA8134 Y  
    Y NRG NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG-GU013 Y  
    Y NRG NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG-GU010 Y  
    Y ECOG-ACRIN EA8191 Pros, Local vs Systemic Thrpy EA8191 Y  
    Y NRG NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG-GU008 Y  
    Y CCTG CCTG-PR26 Prostate, Cast Sensitive, Docetax CCTG-PR26 N  
  LEUK Y SWOG S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O S1925 Y  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
    Y ECOG-ACRIN EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab EA9181 N  
  LUNG     EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno   Y  
    Y SWOG S1827 SCLC, MRI Surveillance +/- PCI S1827 Y  
    Y SWOG S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance S2414 Y  
    Y NRG NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG-LU008 Y  
    Y ALLIANCE A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO A081801 Y  
    Y ECOG-ACRIN EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 EA5182 N  
    Y ALLIANCE S2402 NSCLC, All Stg, Periop Vs Adj Tx CTIU2317-A082304-S2402 N  
  LYMPH Y SWOG S2308 FL, LTB, Mosunetuzumab vs Rituximab S2308 N  
    Y ALLIANCE A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub A052101 Y  
    Y ECOG-ACRIN EA4232 Lymph, Peri T Cell, Auto Stem EA4232 N  
    Y COG AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy AHOD2131 Y  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 Y  
    Y SWOG S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D S2209 Y  
    Y SWOG S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT S2213 Y  
    Y ECOG-ACRIN EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) EAA181 Y  
  OTHER     CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy   Y  
    Y NRG NRGGY036 Ovary, All Stg, Olaparib +/- Bevac NRG-GY036 N  
    Y NRG NRGBN003 Mening, Grd II, Observation vs Irradiation NRG-BN003 Y  
    Y COG AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo AGCT1532 Y Y
    Y CCTG CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG-HN11 Y  
    Y NRG NRGCC014 High Risk, Bone Meta, Radiation Tx NRG-CC014 Y  
    Y ALLIANCE A092205 HN Squamous, Rec/Metas, Pem vs Pem+Cet A092205 Y  
    Y NRG NRGBN011 Brain, Lomustine + Temo vs Temo NRG-BN011 Y  
    Y NRG NRGBN013 Brain, Intact Metas, SRS vs FSRS NRG-BN013 N  
    Y ECOG-ACRIN EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox EA7222 N  
  PEOLC Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y SWOG S2408 Panc Fistula Prevention, Lanreotide S2408 Y  
  PREV Y NRG NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG-CC005 Y  
  SXQOL     NRGCC011 Breast, Survivors, Cog Training   Y  
        NRGCC015 E-Mindfulness After Breast Cancer   Y  
    Y SWOG S2205 ICE COMPRESS: Reduction of CIPN from Taxanes S2205 Y  
    Y ALLIANCE A211901 Cancer survivors who smoke, txt cessation A211901 Y  
    Y COG ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis ACCL1931 Y  
    Y ALLIANCE A222004 Mult, Olanza vs Megestrol for Anorexia A222004 Y  
    Y NRG NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG-CC010 Y  
        A032102      
    Y NRG NRG-HN014 NRG-HN014    

29-NOV-2025 6:11

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

Protocol
Number		 Study Accrual
Goal		 Open
Stat/Date		 Months
Open		 Accrual
as of
01Jan02		 Current Accrual Proj.
Annual
Accr.
Rate		 EXPCLOSE Proj.
Study
Duration
(Years)
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (PEOLC) 491 Y-09/15/17 98 380 380 76 Apr-2027 9.6
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 498 Y-07/16/18 88 436 436 64 Oct-2026 8.3
S1800E S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab (LUNG) 378 Y-04/28/25 7 38 38 72 Jul-2030 5.3
S1802 S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 86 976 976 120 Apr-2028 9.6
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 77 1338 1338 4 Jun-1966 -53.0
S1827 S1827 SCLC, MRI Surveillance +/- PCI (LUNG) 668 Y-01/10/20 70 299 299 36 Jan-2036 > 15 Yrs
S1918 S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH) 422 T-03/19/21 56 136 136 0 > 15 Yrs > 15 Yrs
S1925 S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) 247 Y-12/14/20 59 166 166 36 Jan-2028 7.1
S1931 S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) 336 Y-11/16/20 60 140 140 24 Dec-2033 13.1
S1937 S1937 Blad, Mets, Eribulin + Gem vs SOC (GU) 184 Y-02/16/21 57 120 120 64 Oct-2026 5.7
S2012 S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX) 189 Y-12/02/21 47 131 131 64 Sep-2026 4.8
S2205 S2205 ICE COMPRESS: Reduction of CIPN from Taxanes (SXQOL) 777 Y-03/16/23 32 502 502 284 Oct-2026 3.6
S2206 S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva (BREAST) 960 Y-10/30/23 24 277 277 206 Feb-2029 5.3
S2209 S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D (MMYEL) 510 Y-05/30/23 29 105 105 52 Aug-2033 10.2
S2212 S2212 Breast, TNBC, Neoadj Chemo + Pembro (BREAST) 2400 Y-07/21/23 28 1024 1024 752 Aug-2027 4.1
S2213 S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT (MMYEL) 338 Y-12/01/23 23 29 29 32 Jun-2035 11.6
S2303 S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo (GI) 224 Y-05/06/24 18 69 69 74 Dec-2027 3.6
S2308 S2308 FL, LTB, Mosunetuzumab vs Rituximab (LYMPH) 600 Y-08/01/24 15 220 220 244 May-2027 2.8
S2312 Pros, MCRPC, Cab +/- Carb (GU) 500 Y-09/03/24 14 36 36 32 Apr-2040 > 15 Yrs
S2408 S2408 Panc Fistula Prevention, Lanreotide (PEOLC) 274 Y-02/14/25 9 47 47 90 May-2028 3.3
S2414 S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance (LUNG) 306 Y-03/14/25 8 5 5 8 > 15 Yrs > 15 Yrs
S2417CD S2417CD Colrec Surv, Follow-up w/ CTAC site (CCD) 654 Y-08/04/25 3 11 11 34.602402 > 15 Yrs > 15 Yrs
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.